Stockscreener 앱 받기
1.23
4.24%
0.05
시간 외 거래:
1.26
0.03
+2.44%
전일 마감가:
$1.18
열려 있는:
$1.195
하루 거래량:
6.24M
Relative Volume:
0.80
시가총액:
$416.38M
수익:
$4.47M
순이익/손실:
$-71.67M
주가수익비율:
-5.3063
EPS:
-0.2318
순현금흐름:
$-59.58M
1주 성능:
+3.36%
1개월 성능:
-11.51%
6개월 성능:
-12.77%
1년 성능:
+12.84%
1일 변동 폭
$1.18
$1.28
1주일 범위
$1.16
$1.285
52주 변동 폭
$0.9029
$2.725
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.23 | 413.00M | 4.47M | -71.67M | -59.58M | -0.2318 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 개시 | Canaccord Genuity | Buy |
| 2026-03-11 | 개시 | Oppenheimer | Outperform |
| 2024-10-15 | 개시 | Maxim Group | Buy |
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
Ocugen's gene-agnostic eye therapies could reshape late-stage care - MSN
Ocugen, Inc.'s (NASDAQ:OCGN) Profit Outlook - Moomoo
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen (NASDAQ: OCGN) shareholders back pay, elect directors and confirm new CMO - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
OCGN: All agenda items, including director elections and compensation votes, were approved - TradingView
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen Inc stock (US67577C1053): pipeline updates keep biotech investors watching - AD HOC NEWS
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc stock (US67577C1053): Short interest jumps as investors weigh biotech pipeline - AD HOC NEWS
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data - Stocktwits
· Analyst Forecast - MLQ.ai
How The Ocugen (OCGN) Investment Story Is Evolving Without New Analyst Guidance - Yahoo Finance
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Why Did OCGN Stock Rise Today? - Stocktwits
Why is Ocugen (OCGN) down 10.7% since last earnings report? - MSN
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report? - Yahoo Finance
Ocugen Consolidates Financial Leadership Under New Accounting Officer - The Globe and Mail
Ocugen (NASDAQ: OCGN) CFO assumes principal accounting role - Stock Titan
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care - Yahoo Finance
Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data? - TradingView
OCGN's Catalyst Calendar for Trial Data and Filings Through 2028 - Yahoo Finance
Ocugen Inc stock (US67577C1053): conference schedule and pre-market moves in focus - AD HOC NEWS
Ocugen to Participate in Upcoming June Investor and Industry Conferences - The Manila Times
Eye gene therapy for blindness hits stage at three June events - Stock Titan
Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN
Ocugen (OCGN) Slides 2.13% to $1.38 as Biotech Stock Tests Key Support LevelsMoving Average Ribbon - The Legal Advocate
Ocugen stock dips as Q1 losses widen - MSN
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen Price Target Cut to $11.00/Share From $12.00 by Canaccord Genuity - Moomoo
OCGN Maintained by Canaccord Genuity -- Price Target Lowered to $11 - GuruFocus
Three Speculative Biotech Penny Stocks With Pipeline Catalysts - Kalkine Media
Ocugen Is Maintained at Buy by Canaccord Genuity - Moomoo
Canaccord lowers Ocugen stock price target to $11 on model update By Investing.com - Investing.com South Africa
Canaccord lowers Ocugen stock price target to $11 on model update - Investing.com Australia
CCORF Maintains Ocugen(OCGN.US) With Buy Rating, Cuts Target Price to $11 - Moomoo
FTSE Russell Index Reconstitution Sees Major Changes with Ocugen (OCGN) Joining - GuruFocus
Ocugen (OCGN) Set for Inclusion in Russell 3000 Index Rebalancin - GuruFocus
OCGN Stock Chart | OCUGEN INC (NASDAQ:OCGN) - ChartMill
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):